Results 151 to 160 of about 41,247 (202)

Prioritisation and risk ranking of epidemic-prone diseases for emergency preparedness and response in Eastern Africa using a multi-criteria decision analysis framework, 2023. [PDF]

J Public Health Afr
Kamara N, Guyassa M, Theocharopoulos G, Mohamed AS, Said HM, Pampaka D, Suk J, Riek LP, Aragaw M.   +8 more
europepmc   +1 more source

An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models. [PDF]

Front Immunol
Stromberg ZR, Silva EE, Johnston SC, Johnson DM, Hall D, Adjei EF, Altin JA, Abisoye-Ogunniyan A, Gollott T, He W, Jones IKA, Kwilas S, Lund SJ, Mead HL, Nelson GA, Ouyang L, Peters SKG, Schwedler JL, Trecazzi CZ, Turner MW, Ye C, Bradfute SB, Fischer NO, Hooper JW, Ladner JT, Rasley A, Negrete OA.   +26 more
europepmc   +1 more source

Safety and immunogenicity of rVSVΔG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults (EbolaCov): protocol for a phase IV, single-centre, single-blinded, randomised controlled trial. [PDF]

BMJ Open
Gokani K, Taylor A, Packham A, Musabyimana JP, Shema H, Mutabaruka A, Roche S, Takwoingi Y, Umuhoza C, Nyombayire J, Muvunyi C, Green C.   +11 more
europepmc   +1 more source

Effective communication and public engagement strategies to counter misinformation about infectious diseases. [PDF]

Immunol Cell Biol
Cruickshank S, McKee M, Pagel C.
europepmc   +1 more source

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. [PDF]

J Infect Dis, 2019
Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones D.   +14 more
europepmc   +1 more source

Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review. [PDF]

PLoS Negl Trop Dis
Hamilton DO, Simpson V, Fox T, Lutje V, Kohl A, Ferreira DM, Morton B.   +6 more
europepmc   +1 more source

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. [PDF]

J Infect Dis, 2019
Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M.   +6 more
europepmc   +1 more source

Global epidemiology of vaccine-associated intussusception in children and adolescents, 1968 to 2024: An international pharmacovigilance study. [PDF]

Medicine (Baltimore)
Kim TH, Jo H, Pizzol D, Smith L, Yon DK.
europepmc   +1 more source

Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions. [PDF]

Viruses
Hamza IA, Mao K, Gao C, Hamza H, Zhang H.   +4 more
europepmc   +1 more source

Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease. [PDF]

BMC Infect Dis
Diepvens C, Guttieres D, De Boeck K, Vandaele N, Guariguata L, Decouttere C.   +5 more
europepmc   +1 more source